Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate
Shots:
- Eureka and MSK are eligible to receive up front and ~$1B as development- regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the GPRC5D binder for non-CAR use
- Eureka discovered the GPRC5D binding domain using its E-ALPHA Abs discovery platform- under its collaboration with MSK
- Additionally- targeting GPRC5D may improve the durability of response from current therapies and improves the long-term clinical benefits for patients
Ref: Businesswire | Image: Eureka Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com